Hemostemix Inc. (CVE:HEM – Get Free Report) shares hit a new 52-week low during trading on Monday . The company traded as low as C$0.05 and last traded at C$0.05, with a volume of 20000 shares. The stock had previously closed at C$0.06.
Hemostemix Price Performance
The stock has a market cap of C$4.49 million, a P/E ratio of -1.25 and a beta of 0.55. The business’s 50 day simple moving average is C$0.07 and its 200 day simple moving average is C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Further Reading
- Five stocks we like better than Hemostemix
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Technologies to Challenge NAND Flash Dominance in AI
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Is Zoom Video Stock Getting Too Cheap to Pass Up?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Packaging Corporation of America: Buy The Dip
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
